Lv11
30 积分 2025-08-15 加入
[Expert consensus on endocrine hypertension screening (2025 version)]
15天前
已完结
[The effects of certain preservation processes on the value of food; freezing and dehydration]
3个月前
已关闭
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
3个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
3个月前
已完结
The new dual gastric inhibitory peptide/glucagon‐like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
3个月前
已完结
Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies
5个月前
已完结
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
5个月前
已完结
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
5个月前
已完结
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America
5个月前
已完结
皖公网安备34019202002308
